Table 1. Baseline characteristics in patients with ENKTL.
Characteristics | Total (n = 100) |
TN group (n = 41) |
No TN group (n = 59) |
p-value |
---|---|---|---|---|
Gender | ||||
Male | 77 (77.0) | 29 (29.0) | 48 (48.0) | 0.541 |
Female | 23 (23.0) | 12 (12.0) | 11 (11.0) | |
Age (years) | ||||
> 60 years | 45 (45.0) | 20 (20.0) | 25 (25.0) | 0.529 |
≤ 60 years | 55 (55.0) | 21 (21.0) | 34 (34.0) | |
Regional nodal involvement | ||||
Yes | 31 (31.0) | 16 (16.0) | 15 (15.0) | 0.150 |
No | 69 (69.0) | 25 (25.0) | 44 (44.0) | |
ECOG PS | ||||
≥ 2 | 12 (12.0) | 8 (8.0) | 4 (4.0) | 0.049 |
0-1 | 88 (88.0) | 33 (33.0) | 55 (55.0) | |
Serum LDH level | ||||
High than normal | 29 (29.0) | 15 (15.0) | 14 (14.0) | 0.166 |
Normal | 71 (71.0) | 26 (26.0) | 45 (45.0) | |
B symptoms | ||||
Yes | 21 (21.0) | 12 (12.0) | 9 (9.0) | 0.092 |
No | 79 (79.0) | 29 (29.0) | 50 (50.0) | |
IPI score | ||||
0-2 | 91 (91.0) | 35 (35.0) | 56 (56.0) | 0.102 |
≥ 3 | 9 (9.0) | 6 (6.0) | 3 (3.0) | |
Local tumor invasiveness | ||||
Yes | 22 (22.0) | 10 (10.0) | 12 (12.0) | 0.630 |
No | 78 (78.0) | 31 (31.0) | 47 (47.0) | |
Korean prognostic Index (KPI) | ||||
High KPI score ≥ 3 points | 11 (11.0) | 8 (8.0) | 3 (3.0) | 0.024 |
Glasgow prognostic score (GPS) | ||||
High GPS (2 points) | 31 (31.0) | 17 (17.0) | 14 (14.0) | 0.061 |
CRP/albumin ratio (CAR) | ||||
High CAR | 22 (22.0) | 15 (15.0) | 7 (7.0) | 0.003 |
SUVmax on PET/CT | ||||
Median (range) | 6.4 (2.9-22.3) | 8.4 (2.9-21.1) | 5.2 (3.1-22.3) | 0.008 |
Metabolic tumor volume on PET/CT | ||||
Median (range) | 36.2 (5.1-1164.9) | 84.5 (5.1-1164.9) | 32.8 (6.2-337.0) | <0.001 |
Treatment | ||||
Complete resection group | 37 (37.0) | 13 (13.0) | 24 (24.0) | 0.363 |
CMT | 8 (8.0) | 3 (3.0) | 5 (5.0) | 0.399 |
Chemotherapy only | 29 (29.0) | 10 (10.0) | 19 (19.0) | |
Only biopsy group | 63 (63.0) | 28 (28.0) | 35 (25.0) | 0.363 |
CMT | 56 (56.0) | 26 (26.0) | 30 (30.0) | 0.490 |
Chemotherapy only | 7 (7.0) | 2 (2.0) | 5 (5.0) |
ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; SUVmax, maximum standard uptake value; PET/CT, positron emission tomography; CT, computed tomography, CMT, combined modality treatment (concurrent chemoradiotherapy with chemotherapy)